Prime Minister Keir Starmer has finalised a significant £5.2 billion trade agreement with Switzerland, aimed at boosting service exports and streamlining cross-border travel. The deal, described as a "gold standard" partnership, focuses on enhancing cooperation in financial services, life sciences, and digital technology while simplifying business mobility between the two nations.
Key takeaways
- Estimated £5.2 billion annual boost to UK services exports.
- Introduction of e-gate access for UK nationals at major Swiss airports.
- Visa-free travel for service professionals for up to 90 days annually.
- Planned removal of mobile phone roaming surcharges for travellers.
- Secured intellectual property protections for the life sciences sector.
Boosting services and digital trade
The agreement represents the most significant trade deal for services concluded by the UK, reinforcing its status as a global services superpower. With services accounting for a vast majority of UK economic output, this partnership aims to unlock new opportunities in key sectors including finance, professional services, and digital technologies. By ensuring data continues to flow freely and securely, the deal provides the certainty required for businesses to invest and innovate with confidence.
Streamlining travel and mobility
Business travellers and tourists will benefit from reduced friction at the border. Starting from the end of 2026, UK nationals will be able to use e-gates at Zurich Airport, with Basel and Geneva to follow. Furthermore, the agreement introduces visa-free travel for up to 90 days a year for service professionals, alongside simplified arrangements for intra-company transfers. The government also intends to eliminate mobile roaming charges, making it easier for citizens to stay connected without incurring additional costs.
Protecting life sciences and innovation
Recognising both nations as global leaders in medical research, the agreement codifies strong intellectual property standards. For the first time in a UK free trade agreement, the government has committed to maintaining existing regulatory data protection periods. This stability supports the discovery of new medicines while ensuring the NHS retains access to affordable generic alternatives. Industry leaders have welcomed the move, noting that it provides the necessary framework to drive long-term investment in UK-based research and development.
